TIM3 expression by leukemic and non-leukemic myeloblasts

Cytometry Part B - Clinical Cytometry

Volumn 84 B, Issue 3, 2013, Pages 167-172

  Roth, Christine G ^a   Garner, Kelly ^a   Eyck, Stephen Ten ^a   Boyiadzis, Michael ^a   Kane, Lawrence P ^a   Craig, Fiona E ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

acute myeloid leukemia; flow cytometry; myeloblasts; TIM3

Indexed keywords

MUCIN 3; T CELL IMMUNOGLOBULIN MUCIN 3; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BONE MARROW; CANCER CHEMOTHERAPY; CONTROLLED STUDY; FLUORESCENCE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MEDIAN FLUORESCENCE INTENSITY; MONOCYTE; MYELOBLAST; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BONE MARROW; CELL COUNT; FLOW CYTOMETRY; GENE EXPRESSION; GRANULOCYTE PRECURSOR CELLS; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID, ACUTE; MEMBRANE PROTEINS; MONOCYTES; T-LYMPHOCYTES;

EID: 84876458890     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.21080     Document Type: Article

References (17)

1. Jan M, Chao MP, Cha AC, Alizadeh AA, Gentles AJ, Weissman IL, Majeti R,. Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proc Natl Acad Sci USA 2011; 108: 5009-5014.
2. Kikushige Y, Shima T, Takayanagi S, Urata S, Miyamoto T, Iwasaki H, Takenaka K, Teshima T, Tanaka T, Inagaki Y, et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell 2010; 7: 708-717.
3. Sabatos CA, Chakravarti S, Cha E, Schubart A, Sanchez-Fueyo A, Zheng XX, Coyle AJ, Strom TB, Freeman GJ, Kuchroo VK,. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol 2003; 4: 1102-1110.
4. Sanchez-Fueyo A, Tian J, Picarella D, Domenig C, Zheng XX, Sabatos CA, Manlongat N, Bender O, Kamradt T, Kuchroo VK, et al. Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol 2003; 4: 1093-1101.
5. Lee J, Phong B, Egloff AM, Kane LP,. TIM polymorphisms-Genetics and function. Genes Immun 2011; 12: 595-604.
6. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, Zheng XX, Strom TB, Kuchroo VK,. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005; 6: 1245-1252.
7. Sakai K, Kawata E, Ashihara E, Nakagawa Y, Yamauchi A, Yao H, Nagao R, Tanaka R, Yokota A, Takeuchi M, et al. Galectin-9 ameliorates acute GVH disease through the induction of T-cell apoptosis. Eur J Immunol 2011; 41: 67-75.
8. Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, Manning S, Greenfield EA, Coyle AJ, Sobel RA, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 2002; 415: 536-541.
9. Anderson AC, Anderson DE, Bregoli L, Hastings WD, Kassam N, Lei C, Chandwaskar R, Karman J, Su EW, Hirashima M, et al. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science 2007; 318: 1141-1143.
10. Gleason MK, Lenvik TR, McCullar V, Felices M, O'Brien MS, Cooley SA, Verneris MR, Cichocki F, Holman CJ, Panoskaltsis-Mortari A, et al. Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood 2012; 13: 3064-3072.
11. Larsen HØ, Roug AS, Just T, Brown GD, Hokland P,. Expression of the hMICL in acute myeloid leukemia-a highly reliable disease marker at diagnosis and during follow-up. Cytometry B Clin Cytom 2012; 82B: 3-8.
12. Jun KJ, Lee MJ, Shin DC, Woo MY, Kim K, Park S,. Identification of CCL1 as a gene differentially expressed in CD4 T cells expressing TIM-3. Immune Netw 2011; 11: 203-209.
13. Hoelzinger DB, Smith SE, Mirza N, Dominguez AL, Manrique SZ, Lustgarten J,. Blockade of CCL1 inhibits T regulatory cell suppressive function enhancing tumor immunity without affecting T effector responses. J Immunol 2010; 184: 6833-6842.
14. Wiener Z, Kohalmi B, Pocza P, Jeager J, Tolgyesi G, Toth S, Gorbe E, Papp Z, Falus A,. TIM-3 is expressed in melanoma cells and is upregulated in TGF-beta stimulated mast cells. J Invest Dermatol 2007; 127: 906-914.
15. Lee J, Su EW, Zhu C, Hainline S, Phuah J, Moroco JA, Smithgall TE, Kuchroo VK, Kane LP,. Phosphotyrosine-dependent coupling of Tim-3 to T-cell receptor signaling pathways. Mol Cell Biol 2011; 31: 3963-3974.
16. Kornblau SM, Covey T, Putta S, Cohen A, Woronicz J, Fantl WJ, Gayko U, Cesano A,. Signaling changes in the stem cell factor-AKT-S6 pathway in diagnostic AML samples are associated with disease relapse. Blood Cancer J 2011; 1: e3.
17. Ngiow SF, Teng MW, Smyth MJ,. Prospects for TIM3-targeted antitumor immunotherapy. Cancer Res 2011; 71: 6567-6571.